Novel Prognostic Markers in Renal Cancer
Completed
- Conditions
- Renal Cell Carcinoma
- Registration Number
- NCT01002937
- Lead Sponsor
- Royal Marsden NHS Foundation Trust
- Brief Summary
The purpose of this project is to analyze tumour tissue from a group of subjects with renal cell carcinoma, who have been treated at the Royal Marsden Hospital.
- Detailed Description
Renal cancers have different clinical outcomes. The principal research objective is to study tumour tissue from renal cancer patients and try and understand why some cancers progress more rapidly than others. Further, another key aim of this study is to try and understand why some patients respond to treatment and others do not.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 182
Inclusion Criteria
- The presence of histologically proven renal cell cancer
- The availability of paraffin embedded tissue
- Informed consent needed for tissue taken after January 2006 (date of enforcement of human tissue act)
Exclusion Criteria
- Absence of histological tissue
- Absence of consent to study tissue after January 2006
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The profiling of the expression of signal transduction biomarkers, gene expression, gene copy numbers and effect of mutations of the VHL gene in renal cancer and their relationship to clinical outcomes. 5 years
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
The Royal Marsden NHS Foundation Trust
🇬🇧Sutton, Surrey, United Kingdom